Home » Stocks » IMGN

ImmunoGen, Inc. (IMGN)

Stock Price: $6.43 USD -0.26 (-3.89%)
Updated Jun 21, 2021 12:16 PM EDT - Market open
Market Cap 1.34B
Revenue (ttm) 134.72M
Net Income (ttm) -49.34M
Shares Out 198.84M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $6.43
Previous Close $6.69
Change ($) -0.26
Change (%) -3.89%
Day's Open 6.70
Day's Range 6.41 - 6.70
Day's Volume 1,019,180
52-Week Range 3.38 - 10.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 weeks ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

1 month ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Mature Data from FORWARD II Study of Mirvetuximab with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

1 month ago - Business Wire

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19.

1 month ago - Zacks Investment Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of 10.53% and -7.15%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Immunogen (NASDAQ:IMGN) decreased 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.17), whi...

1 month ago - Benzinga

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results

1 month ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 month ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results

1 month ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting

2 months ago - Business Wire

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

3 months ago - Business Wire

ImmunoGen (IMGN) reports encouraging fourth-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

4 months ago - Zacks Investment Research

The company can thank its partner, Jazz Pharmaceuticals.

4 months ago - The Motley Fool

Shares of Immunogen (NASDAQ:IMGN) moved higher by 2.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 433.33% year over year to $0.16, which ...

4 months ago - Benzinga

ImmunoGen (IMGN) delivered earnings and revenue surprises of 500.00% and 69.54%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and 2020 Financial Results

4 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare Conference

4 months ago - Business Wire

Immunogen (NASDAQ:IMGN) announces its next round of earnings this Friday, February 12. Here is Benzinga's everything-that-matters guide for this Friday's Q4 earnings announcement.

4 months ago - Benzinga

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results

4 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference

5 months ago - Business Wire

ImmunoGen: Update On A Turnaround Story

6 months ago - Seeking Alpha

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

6 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia

6 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences

7 months ago - Business Wire

ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

7 months ago - Zacks Investment Research

ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

ImmunoGen (IMGN) delivered earnings and revenue surprises of 35.00% and 24.65%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

7 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference

7 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - Business Wire

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

India's Gland Pharma, a majority-owned subsidiary of Shanghai Fosun Pharma, was approved for an $814 million IPO on India's Sebi exchange. Huadong Medicine in-licensed greater China rights to an antibod...

7 months ago - Seeking Alpha

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results

7 months ago - Business Wire

ImmunoGen (IMGN) grants exclusive rights to Huadong Medicine for development and commercialization of mirvetuximab soravtansine in Greater China.

8 months ago - Zacks Investment Research

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility

8 months ago - Business Wire

The FDA bestows a Breakthrough Therapy status on ImmunoGen's (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.

8 months ago - Zacks Investment Research

ImmunoGen Inc. (NASDAQ: IMGN) shares pushed higher to start out the week when the U.S.

8 months ago - 24/7 Wall Street

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO

9 months ago - Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C.

9 months ago - Business Wire

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

9 months ago - Zacks Investment Research

About IMGN

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 16, 1989
CEO
Mark Enyedy
Employees
79
Stock Exchange
NASDAQ
Ticker Symbol
IMGN
Full Company Profile

Financial Performance

In 2020, ImmunoGen's revenue was $132.30 million, an increase of 60.81% compared to the previous year's $82.27 million. Losses were -$44.37 million, -57.39% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for ImmunoGen stock is "Buy." The 12-month stock price forecast is 9.93, which is an increase of 54.43% from the latest price.

Price Target
$9.93
(54.43% upside)
Analyst Consensus: Buy